ANI Pharmaceuticals (ANIP) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $2.21
- Estimate
- $2.04
- Surprise
- +8.2%
- Revenue (period 2026-06-30)
- $266.0M
- Score at report (before → after)
- 7.1 → 7.2/10
Revenue source: xbrl.
How the report landed
ANI Pharmaceuticals (ANIP) beat the $2.04 estimate with diluted EPS of $2.21 — a clear 8.2% upside surprise. TrendMatrix's engine moved from Buy (Wait) (7.1/10) to Hold at 7.2/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ANIP Hold at 6.8/10.
4 of the last 4 quarters beat the estimate; this quarter's +8.2% surprise compares with a +24.8% four-quarter average. Next scheduled report: 2026-11-06.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.2 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Supplier: single-source API per product
- Concentration risk — Supplier: Cortrophin Gel and ILUVIEN contract manufacturers
- Leverage penalty (D/E 1.0): -0.5
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $70.19
- Price target
- $94.29
- Stop
- $67.49
- Upside to target
- +34.3%
- Reward-to-risk
- 6.6:1
The stock trades at 15.3× trailing but 6.7× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
ANIP at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $1.61B
- P/E (fwd)
- 6.7
- P/E (ttm)
- 15.3
- 52-week range
- $69.58–$99.39
- Off 52-week high
- 29.4%
- RSI (14)
- 31
- Volume vs avg
- 1.08×
- Score today
- 6.8/10